Overactive Bladder Treatment Market Research Report – Forecast to 2027

Overactive Bladder Treatment Market Research Report: By Pharmacotherapy (Anticholinergic, Botox, Others), by Non-Pharmacological Treatment (Behavioral Therapy, Others), by Disease (Idiopathic Overactive Bladder, Others) - Forecast Till 2027

ID: MRFR/Pharma/4787-HCR | February 2021 | Region: Global | 100 pages

Overactive Bladder Treatment Market Scenario:

The overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the overactive bladder treatment market is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.

Overactive Bladder (OAB) is a symptom syndrome characterized by urinary urgency. Numerous factors such as the growing prevalence of Overactive Bladder (OAB) coupled with the rising geriatric population, increasing occurrences of Parkinson’s disease, and multiple sclerosis and stroke are likely to drive the growth of the market during the forecast period. For instance, according to the data stated by the Official Foundation of the American Urological Association, in 2016, approximately 33 million Americans had an overactive bladder. It also mentioned that around 30% of men and 40% of women in the US have the symptoms of overactive bladder. Moreover, the development of innovative intravesical therapies and increasing marketing activities by pharma companies contribute to the growth of the market.

Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.

Research Methodology

Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on primary and secondary research.

Primary Research

Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with the key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.

Secondary Research

Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the overactive bladder treatment market. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, & developments related to the market and Treatment Perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases, and many others.

Company Profiles

Astellas Pharma Inc.

Pfizer, Inc.

Teva Pharmaceutical

Allergan, Plc.

Mylan N.V.

Endo International Plc

Hisamitsu Pharmaceutical Co., Inc.

Sanofi S. A.

Aurobindo Pharma Limited

Johnson & Johnson

Intas Pharmaceuticals Ltd.

Apotex Inc.

Macleods Pharmaceuticals Ltd.

Medtronic PLC

Cogentix Medical, Inc.

Others

Segmentation

The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.

On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.

The overactive bladder treatment global market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.

On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and the overactive bladder in other disorders.

Geographically, the overactive bladder treatment global market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.

The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.

The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.

The overactive bladder treatment global market in the Middle East and Africa is segmented into the Middle East and Africa.

Regional Market Summary

The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.

Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.

The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.

The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.

Global Overactive Bladder Treatment Market, by Pharmacotherapy

Anticholinergics

Solifenacin

Oxybutynin

Fesoterodine

Darifenacin

Tolterodine

Trospium

Others

Botox

Mirabegron

Neurostimulation

Others

Global Overactive Bladder Treatment Market, by Non-Pharmacological Treatment

Dietary and Fluid Modifications

Behavioral Therapy

Pelvic Floor Muscle Rehabilitation

Others

Global Overactive Bladder Treatment Market, by Disease

Idiopathic Overactive Bladder

Neurogenic Overactive Bladder

Overactive Bladder in Parkinson’s Disease

Overactive Bladder in Stroke

Overactive Bladder in Multiple Sclerosis

Overactive Bladder in Spinal Cord Injury

Overactive Bladder in Other Disorders

Global Overactive Bladder Treatment Market, by Region

North America

Canada

Europe

Germany

France

Italy

Spain

Rest of Europe

Asia-Pacific

China

Japan

India

Australia

South Korea

Rest of Asia-Pacific

Rest of the World

Middle East

Africa

Latin America

Intended Audience

Drug manufacturers, vendors, and distributors

Academic and government research institutes

Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs)

Venture capitalists and investors

Report Scope:

Report Attribute/Metric	Details
Market Size	Significant Value
CAGR	2018-2023: ~ 3.1%
Base Year	2019
Forecast Period	2027
Historical Data	2018
Forecast Units	Value (USD Million)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Pharmacotherapy, Non-Pharmacological Treatment, and Disease
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Astellas Pharma Inc., Pfizer, Inc., Teva Pharmaceutical, Allergan, Plc. , Mylan N.V. , Endo International Plc , Hisamitsu Pharmaceutical Co., Inc., Sanofi S. A., Aurobindo Pharma Limited , Johnson & Johnson, Intas Pharmaceuticals Ltd. , Apotex Inc. , Macleods Pharmaceuticals Ltd. , Medtronic PLC, Cogentix Medical, Inc.
Key Market Opportunities	Development of innovative intravesical therapies Increasing marketing activities by pharma companies
Key Market Drivers	Rising geriatric population Increasing occurrences of parkinson’s disease and multiple sclerosis and stroke

Speak to Analyst Ask for Customization

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Overactive Bladder Treatment Market, by Pharmacotherapy

6.1 Introduction

6.2 Anticholinergics

6.2.1 Solifenacin

Market Estimates & Forecast by region, 2020–2027